GEL Labs Newsletter: Research Weekly

Research Weekly Aug 6, 2026: The Most Studied Research Peptides of the Last Decade, Spotlight: Tesamorelin
This week, we're taking a closer look at the research compounds that have attracted the most scientific attention over the past decade, featuring Tesamorelin in this week's Research Spotlight. Read more...
Research Weekly Jul 30, 2026: Six Peptides Advanced. One Did Not. What Comes Next?
Last week’s FDA advisory meeting produced one of the most closely watched peptide-compounding discussions in recent memory.  This week, we’re breaking down the final results, why DSIP was treated differently, what happens next, and which peptides are already scheduled for the next FDA review. Read more...
Research Weekly Jul 24, 2026: FDA Panel Backs Four Peptide Groups - Spotlight On: AOD-9604
The first day of the FDA’s closely watched peptide meeting has concluded—and the results went against the recommendations made by FDA staff. Plus Spotlight On: AOD-9604 Read more...
Research Weekly Jul 17, 2026: One Week Until FDA’s Peptide Meeting & Artificial Intelligence Inbox
This week, the FDA peptide story moves closer to the committee room. Plus, the growing use of artificial intelligence and automated screening to design more complex cyclic peptides. Read more...
Research Weekly July 10, 2026: What the FDA’s peptide documents actually say...
Last week, we covered the FDA briefing documents released ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting. Since then, we’ve spent more time going through the materials. Read more...
Research Weekly Jul 3, 2026: FDA Peptide Briefing Docs + New Peptide-Chemistry Research
This week, we’re looking at two developments that say a lot about where the peptide space is heading: FDA’s latest briefing materials ahead of the July advisory committee meeting, and new research on peptide synthesis methods that could shape how more complex peptide structures are made and studied. Read more...
Research Weekly June 24, 2026: FDA peptide review + MOTS-C trial watch
A closer look at upcoming peptide regulation and why MOTS-C remains one of the more closely watched mitochondrial-derived peptides. Read more...